The 2bind services and assays are tailored for different phases of a drug discovery process. In the hit identification phase, we offer special MST high-throughput screening (MST HTS) assays. This ensures highest throughput with minimal sample consumption and costs, while still telling true steady-state binding affinities. The hit validation phase comprises various biophysical assay formats for confirming and validating initial screening hits. The hit characterization phase features a variety of specialized assays to tell affinities, kinetics, and thermodynamics of a drug lead canditate.
2bind is your one-stop shop for early drug discovery hit identification and high-throughput screening using MST and nanoDSF. We cover all steps from assay development to high-throughput screening. We provide in-house compound and bioactive, tool-compound librariers as well as specialized fragment libraries. Our compound handling lab is equipped with high-throughput, contact-less Labcyte Echo systems and liquid handling robots.
Click here for a fragment-based drug discovery (FBDD) special!
Comprehensive assay development for proteins, DNA, and RNA with respect to affinity, stability, control selection, robustness, and reproducibility.
150 000 small molecule compound library
5 000 bioactive tool compound library
20 000 fragment library
Contact-less, ultrasound-based direct dilution using Labcyte Echo systems. Minimal ligand consumption (single digit nanoliters per sample).
Liquid-handling robotic platforms for preparation of screening plates and assay samples.
True biophysical hit identification and screening using high-throughput MST and nanoDSF setups.
All the right tools for the job! We offer the full portfolio of state-of-the art biophysical assay development using MicroScale Thermophoresis and nanoDSF. Our methods and assays are certified by NanoTemper Technologies (Munich, Germany). The 2bind assay development covers assay setup, establishment of required technical parameters, selection and establishment of positive and negative controls, robustness testing, and transfer to a high-throughput setup.
Biophysical hit screening made easy. 2bind’s partner-network gives you access to computational ligand pre-screening. This allows in silico identification of binders from up to 3 million compound structures. 2bind also offers high-fidelity in-house fragment libraries (n = 20 000) for fragment-based drug discovery as well as specialized small molecule (n = 150 000) and bioactive tool compound (n = 5 000) collections.
Target- or ligand-based pre-screening using novel in silico, fingerprint-based algorithms.
> Reduction of library size and complexity.
> Reduction of screening time and costs.
Flexible sourcing of specialized fragment libraries from partners and vendors.
> Tailored selection of library size.
> Specific selection of chemical space.
150.000 small molecule collection and 5050 bioactive tool compound collection from our partner Assay.Works.
> Seamless integration into our processes.
Put MST high-throughput screening to a whole new level. By using ultrasound-based, direct dilution systems (LabCyte Echo platform) for fragment and compound handling we can truly unlock the high-throughput potential of MST and nanoDSF. The LabCyte Echo system enables ultra-fast, contact-less dilution of DMSO stocks with just single-digit nanoliter volumes. No plastic ware consumption, no sample carryover, no cross-contamination, and absolut minimum compound use! Read more on how the Echo system works.
True biophysical, high-throughput screening using MicroScale Thermophoresis (MST) and nanoDSF. Don’t get only a yes-or-no answer for your fragments or compounds. Get their true steady-state affinity. MST and nanoDSF offer the absolute lowest sample consumption for biophysical screening on the market. Screenings of thousand of compounds can be performed with just a couple of hundred microliters of protein solution.
100 full, 12-point dose-response curves in 10 hours with true steady-state affinity (KD) determination.
Up to 600 single-dose analyses in 10 hours.
> Online quality-controls (target instability, precipitation, and adhesion effects).
> Classification of binders, non-binders, fluorescent-effects, target-aggregation-inducing compounds, etc.
48 target-ligand pairs in parallel with determination of ligand-induced thermal shift of protein denaturation.
480 ligand analyses in 10 hours.
> Online quality-controls (target unfolding, ligand fluorescence).
> Identification of target-aggregation-inducing ligands possible by light scattering.
Hit Validation + Hit Characterization
A number of biophysical paramters is of great intereset in the Hit Validation phase of a drug discovery projects. These include precise steady-state binding affinity to the screening target (KD), as well as the kinetic (kon, koff) and thermodynamic (ΔG, ΔH, ΔS) parameters of hit-target interactions. We cover all these questions with our portfolio of MST, nanoDSF, BLI, and ITC methods.
In hit-to-lead stages, a lower number of drug candidates are typically analyzed with respect to more advanced binding parameters, like stoichiometry, possible competition effects, or their mode-of-action. Moreover, off-target effects have to be carefully investigated, for example by analyzing hit-target interactions in various biological liquids like serum, celly lysate, blood plasma, urine, or the like. Benefit from our higly-variable timelines and project setups to choose the right assay at the right time of the hit-to-lead phase, just as you like.